comparemela.com

Latest Breaking News On - Shanghai yingli pharmaceutical co ltd - Page 1 : comparemela.com

280 Bio receives IND approval from the FDA for YL-17231

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced a presentation featuring the Company s lead development

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.